Detalles de la búsqueda
1.
[Safety and feasibility of outpatient management in relapsed/refractory lymphoma treated with pegfilgrastim after multi-agent salvage therapy: a single-center, open-label, non-randomized, prospective interventional study].
Rinsho Ketsueki;
64(7): 596-607, 2023.
Artículo
en Japonés
| MEDLINE | ID: mdl-37544718
2.
Real-world data analysis of perioperative chemotherapy patterns, G-CSF use, and FN status in patients with early breast cancer.
Breast Cancer Res Treat;
201(2): 265-273, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37410318
3.
Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis).
BMC Cancer;
21(1): 358, 2021 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33823836
4.
Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).
Support Care Cancer;
28(2): 571-579, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31093770
5.
Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan.
Support Care Cancer;
25(11): 3313-3320, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28551843
Resultados
1 -
5
de 5
1
Próxima >
>>